Deals
Bayer Mulls Dropping Monsanto Name as Brand Headache Cure
- Executives aiming to build on consumer trust in Europe
- The companies can “get beyond this image and reputation thing”
Bayer, Monsanto CEOs on $66 Billion Merger
This article is for subscribers only.
With Bayer AG’s proposed $66 billion purchase of Monsanto Co., the company that invented Aspirin is poised to take on one of the world’s biggest corporate headaches. A potential cure: dropping the Monsanto name.
The German drug and chemical conglomerate is considering that move to avoid sullying its reputation, according to people familiar with internal discussions at Bayer who asked not to be named because the talks are private. No decision has been made, and Bayer’s managers will have some time to think: thanks to antitrust reviews in some 30 jurisdictions worldwide, the purchase isn’t likely to be completed before late 2017.